Trial Profile

Phase 2 trial of CTX110

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTX 110 (Primary)
Indications B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use

Most Recent Events

16 Dec 2022 New trial record
12 Dec 2022 According to a CRISPR Therapeutics media release, the company initiated this study based on discussions with regulatory agencies. Dosing in this trial is expected to begin in early 2023 using drug product manufactured with a commercial-ready process and specifications.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com